

Peter H Sykes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/848294/publications.pdf>

Version: 2024-02-01

80
papers

2,275
citations

304602

22
h-index

233338

45
g-index

82
all docs

82
docs citations

82
times ranked

3063
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 772-780.	5.1	296
2	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1224.	3.8	271
3	MALIGNANT PROGRESSION OF ANAL INTRA-EPITHELIAL NEOPLASIA. <i>ANZ Journal of Surgery</i> , 2006, 76, 715-717.	0.3	221
4	Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. <i>Experimental Cell Research</i> , 2013, 319, 75-87.	1.2	139
5	Low Ascorbate Levels Are Associated with Increased Hypoxia-Inducible Factor-1 Activity and an Aggressive Tumor Phenotype in Endometrial Cancer. <i>Cancer Research</i> , 2010, 70, 5749-5758.	0.4	116
6	The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 38.	1.8	112
7	Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 1147-1153.	1.3	86
8	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Endometrial Stromal Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S67-S72.	1.2	75
9	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019, 154, 531-538.	0.6	49
10	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. <i>Gynecologic Oncology</i> , 2021, 161, 143-151.	0.6	46
11	Cellular transfer and AFM imaging of cancer cells using Bioimprint. <i>Journal of Nanobiotechnology</i> , 2006, 4, 1.	4.2	44
12	Cytotoxicity and cellular uptake of different sized gold nanoparticles in ovarian cancer cells. <i>Nanotechnology</i> , 2017, 28, 475101.	1.3	44
13	Gene and protein expression signature of endometrial glandular and stromal compartments during the window of implantation. <i>Fertility and Sterility</i> , 2012, 97, 1365-1373.e2.	0.5	43
14	High-grade vulval intraepithelial neoplasia (VIN 3): a retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989-1999. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2002, 42, 75-80.	0.4	39
15	Acceptability of self-taken vaginal HPV sample for cervical screening among an under-screened Indigenous population. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 301-307.	0.4	34
16	Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 2155-2162.	1.3	33
17	Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF- κ B protein. <i>Journal of Ovarian Research</i> , 2016, 9, 84.	1.3	31
18	Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. <i>Gynecologic Oncology</i> , 2012, 125, 520-525.	0.6	27

#	ARTICLE	IF	CITATIONS
19	Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG. <i>Gynecologic Oncology</i> , 2009, 113, 374-378.	0.6	25
20	Postpartum curettage: An audit of 200 cases. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 368-371.	0.4	24
21	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1748-1756.	1.2	24
22	Improving survival disparities in cervical cancer between Māori and non-Māori women in New Zealand: a national retrospective cohort study. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 193-199.	0.8	23
23	Reaching under-screened/never-screened indigenous peoples with human papilloma virus self-testing: A community-based cluster randomised controlled trial. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, 135-141.	0.4	23
24	Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines. <i>Obstetrics and Gynecology International</i> , 2015, 2015, 1-14.	0.5	22
25	In the secretory endometria of women, luminal epithelia exhibit gene and protein expressions that differ from those of glandular epithelia. <i>Fertility and Sterility</i> , 2014, 102, 307-317.e7.	0.5	20
26	Primary breast cancer of the vulva: Case report and literature review. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2007, 47, 77-79.	0.4	19
27	Seed mediated synthesis of highly mono-dispersed gold nanoparticles in the presence of hydroquinone. <i>Nanotechnology</i> , 2016, 27, 355601.	1.3	19
28	New approaches to cancer care in a COVID-19 world. <i>Lancet Oncology</i> , The, 2020, 21, e339-e340.	5.1	18
29	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. <i>Gynecologic Oncology</i> , 2021, 163, 72-78.	0.6	17
30	Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades. <i>Gynecologic Oncology</i> , 2012, 125, 214-219.	0.6	16
31	Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. <i>Gynecologic Oncology</i> , 2017, 146, 273-278.	0.6	15
32	Does the endometrial gene expression of fertile women vary within and between cycles?. <i>Human Reproduction</i> , 2018, 33, 452-463.	0.4	15
33	Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2010, 50, 164-167.	0.4	14
34	Cell-like features imprinted in the physical nano- and micro-topography of the environment modify the responses to anti-cancer drugs of endometrial cancer cells. <i>Biofabrication</i> , 2017, 9, 015017.	3.7	14
35	Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016). <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 6, 77-82.	4.5	14
36	Tumour Initiation: a Discussion on Evidence for a "Load-Trigger" Mechanism. <i>Cell Biochemistry and Biophysics</i> , 2019, 77, 293-308.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Desmoplastic melanoma of the vulva. <i>Pathology</i> , 1997, 29, 241-245.	0.3	12
38	Trophoblastic Differentiation in an Endometrial Carcinoma. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1998, 38, 472-473.	0.4	12
39	Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand. <i>Cancer Causes and Control</i> , 2010, 21, 209-214.	0.8	12
40	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2011, 120, 179-184.	0.6	12
41	The characteristics of Ishikawa endometrial cancer cells are modified by substrate topography with cell-like features and the polymer surface. <i>International Journal of Nanomedicine</i> , 2015, 10, 4883.	3.3	12
42	Pathological process has a crucial role in sentinel node biopsy for vulvar cancer. <i>Gynecologic Oncology</i> , 2019, 153, 292-296.	0.6	12
43	Observational Management of CIN 2 in Young Women: A Prospective Multicenter Trial. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 343-347.	0.9	11
44	Enhanced Recovery After Surgery for Suspected Ovarian Malignancy. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1046-1050.	1.2	11
45	A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models. <i>Oncology and Therapy</i> , 2016, 4, 257-274.	1.0	10
46	Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 222.e1-222.e13.	0.7	9
47	Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. <i>BMC Infectious Diseases</i> , 2014, 14, 374.	1.3	8
48	PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5524-5524.	0.8	8
49	The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models. <i>Cancers</i> , 2022, 14, 395.	1.7	8
50	Does regular cervical screening protect women from microinvasive squamous cell carcinoma of the cervix? A retrospective case?control study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 807-809.	1.1	7
51	Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. <i>Cancer Letters</i> , 2018, 420, 168-181.	3.2	7
52	Evaluation of guidelines for observational management of cervical intraepithelial neoplasia 2 in young women. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 408.e1-408.e11.	0.7	7
53	Uterine cancer: exploring access to services in the public health system. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2014, 54, 457-461.	0.4	6
54	Wrong place at the wrong time: A case of cervical embryonal rhabdomyosarcoma in pregnancy. <i>Gynecologic Oncology Reports</i> , 2015, 12, 77-79.	0.3	6

#	ARTICLE	IF	CITATIONS
55	The extracellular topographical environment influences ovarian cancer cell behaviour. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 1188-1194.	1.0	6
56	Low-grade serous ovarian carcinoma: A comprehensive literature review. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 27-33.	0.4	6
57	Modulation of vascular endothelial growth factor and thymidine phosphorylase in normal human endometrial stromal cells. <i>Fertility and Sterility</i> , 2004, 82, 1048-1053.	0.5	5
58	Clinical utility of magnetic resonance imaging and the preoperative identification of low risk endometrial cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004, 44, 419-422.	0.4	4
59	Initial observation of CIN2 does not appear to reduce quality of life in women under 25 years of age. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2017, 57, 473-478.	0.4	4
60	Extracellular biophysical environment: Guilty of being a modulator of drug sensitivity in ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 180-186.	1.0	4
61	Deciphering Biophysical Modulation in Ovarian Cancer Cells. <i>Cell Biochemistry and Biophysics</i> , 2021, 79, 375-386.	0.9	4
62	Collagen I dysregulation is pivotal for ovarian cancer progression. <i>Tissue and Cell</i> , 2022, 74, 101704.	1.0	4
63	Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. <i>BMJ Open</i> , 2017, 7, e017576.	0.8	3
64	Use of direct oral anticoagulants for postoperative venous thromboembolism prophylaxis after surgery for gynecologic malignancies. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 189-194.	1.2	3
65	Retrospective analysis on timeframes of referral, diagnosis and treatment of patients with endometrial carcinomas in Dunedin Hospital, 2008-2011. <i>New Zealand Medical Journal</i> , 2013, 126, 84-95.	0.5	3
66	Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1991-2002.	1.2	3
67	The Impact of Outpatient Booking Systems on Waiting Times for Investigation of Suspected Cancer: The Case of Post-Menopausal Bleeding. <i>Clinical Ovarian and Other Gynecological Cancer</i> , 2012, 5, 87-93.	0.1	2
68	A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. <i>Journal of Ovarian Research</i> , 2015, 8, 43.	1.3	2
69	Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2343.	1.3	2
70	Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women. <i>New Zealand Medical Journal</i> , 2020, 133, 72-84.	0.5	2
71	Trends in the diagnosis of high-grade cervical abnormalities in young women in the post-vaccination era. <i>New Zealand Medical Journal</i> , 2020, 133, 50-63.	0.5	2
72	Is there a role for colposcopy in the follow-up of treated low grade squamous intraepithelial lesions?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004, 44, 574-576.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Providing care for women with gynaecological malignancy: the need for a coordinated national approach. <i>New Zealand Medical Journal</i> , 2012, 125, 57-65.	0.5	1
74	Dermatomyositis and Ovarian Cancer: A Rare Occurrence but a Significant Association. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1994, 34, 616-617.	0.4	0
75	Human papilloma virus is detectable by the Hybrid Capture 2 test in cervical smear samples from women over 40 years of age with high-grade squamous intraepithelial lesions. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 457-459.	0.4	0
76	Trends in the overall survival rates in women with advanced ovarian cancer in a single tertiary centre in New Zealand. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 861-866.	0.4	0
77	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5621-TPS5621.	0.8	0
78	A Doctrine of Ovarian Cancer Translational Research Needs Revisiting. <i>International Journal of Cancer Management</i> , 2020, 13, .	0.2	0
79	Findings and outcome of teenage women referred for colposcopy at Christchurch Women's Hospital, New Zealand. <i>New Zealand Medical Journal</i> , 2005, 118, U1350.	0.5	0
80	Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand. <i>New Zealand Medical Journal</i> , 2019, 132, 26-35.	0.5	0